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Abstract
Background: Cardioembolic stroke generally results in more severe disability, since it typically has a
larger ischemic area than the other types of ischemic stroke. However, it is difficult to differentiate
cardioembolic stroke from non-cardioembolic stroke (atherothrombotic stroke and lacunar stroke). In
this study, we evaluated the levels of plasma brain natriuretic peptide in acute ischemic stroke patients
with cardioembolic stroke or non-cardioembolic stroke, and assessed the prediction factors of plasma
brain natriuretic peptide and whether we could differentiate between stroke subtypes on the basis of
plasma brain natriuretic peptide concentrations in addition to patient's clinical variables.
Methods: Our patient cohort consisted of 131 consecutive patients with acute cerebral infarction who
were admitted to Kagawa University School of Medicine Hospital from January 1, 2005 to December 31,
2007. The mean age of patients (43 females, 88 males) was 69.6 ± 10.1 years. Sixty-two patients had
cardioembolic stroke; the remaining 69 patients had non-cardioembolic stroke (including
atherothrombotic stroke, lacunar stroke, or the other). Clinical variables and the plasma brain natriuretic
peptide were evaluated in all patients.
Results: Plasma brain natriuretic peptide was linearly associated with atrial fibrillation, heart failure,
chronic renal failure, and left atrial diameter, independently (F4,126 = 27.6, p < 0.0001; adjusted R2 = 0.45).
Furthermore, atrial fibrillation, mitral regurgitation, plasma brain natriuretic peptide (> 77 pg/ml), and left
atrial diameter (> 36 mm) were statistically significant independent predictors of cardioembolic stroke in
the multivariable setting (Χ2 = 127.5, p < 0.001).
Conclusion: It was suggested that cardioembolic stroke was strongly predicted with atrial fibrillation and
plasma brain natriuretic peptide. Plasma brain natriuretic peptide can be a surrogate marker for
cardioembolic stroke.
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Background
Stroke is a major cause of serious long-term disability and
death [1]. Acute ischemic stroke accounts for approxi-
mately 70% of all strokes, and is caused by embolic or
atherosclerotic occlusion in the cerebral vessels. Further-
more, cardioembolic stroke generally results in more
severe disability, since it typically has a larger ischemic
area than the other types of ischemic stroke.
However, it is difficult to diagnose the ischemic stroke
subtypes exactly at admission. And, it takes 2 weeks to
identify paroxysmal atrial fibrillation (Af) since standard
electrocardiography (ECG), 24 hour ECG recording, and
14-days ambulatory ECG monitoring is necessary [2]. Fur-
thermore, there are the patients with patent foramen ovale
(PFO), pulmonary arteriovenous fistula, or the others that
are the causes of cardioembolic stroke and show basically
normal finding in ECG and transthoracic echocardiogram
(TTE). It nevertheless remains important to differentiate
cardioembolic stroke from non-cardioembolic stroke
(atherothrombotic stroke and lacunar stroke), since acute
and secondary prevention treatment differ in these cases:
in cardioembolic stroke, anti-coagulant agents (e.g. warfa-
rin) are most effective for secondary prevention, whereas
in non-cardioembolic stroke, anti-platelet agents (e.g.
aspirin, cilostazol, or clopidogrel) are commonly used in
Japan.
Plasma brain natriuretic peptide (BNP) concentration has
seen widespread use in Japan as a biochemical marker of
heart failure [3]. In the same time, plasma BNP is known
to increase in patients with Af [4], cardiomyopathy [5],
heart failure [6], myocardial infarction [7], or chronic
renal failure [8]; but little is known about plasma BNP in
ischemic stroke. In this study, plasma BNP was evaluated
in a cohort of acute ischemic stroke patients, with the goal
of assessing whether one could differentiate cardioem-
bolic stroke from non-cardioembolic stroke with non-
invasive examination.
Methods
Subjects
One hundred thirty one consecutive patients with acute
ischemic stroke were admitted to Kagawa University
School of Medicine Hospital within 24 hours after their
stroke onset from January 1, 2005 to December 31, 2007.
In these patients, there were 25 patients who variously
had heart failure (n = 14; serologic data of left ventricular
ejection fraction < 40%), cardiomyopathy (n = 8; past
diagnosis with echocardiography and coronary angiogra-
phy), old myocardial infarction (n = 11; suggestive ECG
changes and clear evidence of asynergy with echocardiog-
raphy) or chronic renal failure (n = 12; serologic data of
blood urea nitrogen > 30 mg/dl, creatinine > 1.5 mg/dl, or
creatinine clearance < 70 ml/min) all of which were
known to increase plasma BNP.
Plasma BNP was evaluated at the first morning after
admission in all 131 patients. In the present study, Af was
diagnosed as permanent Af or paroxysmal Af, with stand-
ard ECG, 24-hour ECG recording, and 14-day ambulatory
ECG monitoring [2]. Patients were evaluated national
institute of health stroke scale (NIHSS) score at their
admission, and were diagnosed as having cardioembolic
stroke or non-cardioembolic stroke (including athero-
thrombotic stroke, lacunar stroke, or the other), using
echocardiography, brain computed tomography, mag-
netic resonance imaging, magnetic resonance angiogra-
phy, and carotid ultrasonography by two stroke specialists
(N.H., T.T.). Final diagnosis of stroke subtype was made at
the patients' discharge based on Trial of Org 10172 in
Acute Stroke Treatment (TOAST) criteria [9]. We blinded
the BNP value to the physicians who diagnosed the stroke
subtypes. Informed consent was obtained from all
patients; and, this study was approved by the investiga-
tional review board of the Kagawa University School of
Medicine.
Echocardiography
TTE was performed in all patients, and left ventricular
(LV) ejection fraction was calculated as (1 – end-systolic
volume/end-diastolic volume) × 100. Chamber size was
measured by the modified Simpson's method on 2-
dimensional echocardiography [10]. LV end-diastolic
dimension was measured on M-mode echocardiography
[11]. Transesophageal echocardiography (TEE) was per-
formed to measure left atrial appendage (LAA) flow and
detect PFO and shunt flow from right to left atrium.
Plasma Brain Natriuretic Peptide (BNP)
Blood samples were taken on the first morning after
admission. Blood was immediately separated into chilled
tubes containing potassium ethylenediaminetetraacetic
acid and centrifuged for 30 minutes. Plasma BNP concen-
trations were then determined with a specific immunora-
diometric assay (Shionoria BNP Kit, Shionogi Co., Ltd.,
Tokyo, Japan) [12]. Our normal range of BNP is less than
18.4 pg/ml.
Statistical analysis
Summary statistics were expressed as mean ± standard
deviation or medians (ranges of 25 to 75 percentile) for
continuous variables, and frequencies and percentages for
discrete variables. To estimate the reproducibility of meas-
urements of dimension and flow velocity with echocardi-
ography, the echocardiography of 10 volunteers were
evaluated by 8 trained cardiologists who had evaluated
echocardiography in this study. Intraobserver coefficients
of variation of dimension and flow velocity of echocardi-BMC Neurology 2008, 8:45 http://www.biomedcentral.com/1471-2377/8/45
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ography were 7.0 and 9.2%, respectively, and interob-
server coefficients of variation of dimension and area of
echocardiography were 9.6 and 10.8%, respectively. Com-
parisons of clinical characteristics and ultrasonographic
measurements between the stroke subtypes were made
with either one way-ANOVA with Bonferroni's correction
for multiple comparisons (for continuous variables) or
Fisher exact tests (for discrete variables). Differences in
NIHSS score among groups were examined using Kruskal-
Wallis test. Multiple linear regression analysis was used to
assess whether plasma BNP could be adequately predicted
from clinical variables. Our regression strategy was to
undertake all subsets regressions, with no forced inde-
pendent variables. The regression models were deter-
mined from this procedure, and represented the best (in
terms of maximal R2) of all possible regression models.
Each of the independent variables in the regression mod-
els was nominally significant, with p < 0.05. Multivariable
logistic regression was utilized to assess the relative
importance of variables that was found an association
with cardioembolic stroke in initial univariate analyses.
Results
Our study cohort consisted of 131 patients: 62 cardioem-
bolic stroke patients and 69 patients with non-cardioem-
bolic stroke (24 atherothrombotic stroke, 21 lacunar
stroke, and 24 undetermined subtype of ischemic stroke).
All of the paroxysmal Af patients were in sinus rhythm at
admission. In these patients, there were 25 patients who
variously had heart failure (n = 14), cardiomyopathy (n =
8), old myocardial infarction (n = 11), or chronic renal
failure (n = 12). Clinical characteristics of the patients
were given in Table 1. There were no significant differ-
ences between cardioembolic stroke and non-cardioem-
bolic stroke in these parameters, with the exceptions of
plasma BNP and distribution of Af and mitral regurgita-
tion: plasma BNP was significantly increased in the cardi-
oembolic stroke patients compared with the non-
Table 1: Clinical characteristics and cardiac function ultrasonographic variables.
Variable Non-Cardioembolic Stroke
(n = 69)
Cardioembolic Stroke
(n = 62)
Age (years) 69.9 ± 9.9 69.8 ± 10.4
Sex, F/M 19/50 24/38
Systolic Blood Pressure (mmHg) 177 ± 11 182 ± 14
Body Mass Index, kg/m2 23.6 ± 2.5 24.1 ± 3.4
Blood Urea Nitrogen, mg/dl 15.2 ± 5.6 13.7 ± 4.3
Creatinine, mg/dl 1.10 ± 0.27 1.06 ± 0.37
Hypertension, yes/no (%) 46/23 (66.7%) 41/21 (66.1%)
Dislipidemia, yes/no (%) 15/54 (21.7%) 16/46 (25.8%)
Diabetes Mellitus, yes/no (%) 17/52 (24.6%) 18/44 (29.0%)
Smoking, yes/no (%) 42/27 (60.9%) 34/28 (54.8%)
Atrial fibrillation (including permanent and paroxysmal Af), yes/no (%) 2/67 (2.9%) 49/13 (79.0%)**
Mitral stenosis, yes/no (%) 0/69 (0%) 3/59 (4.8%)
Mitral regurgitation, yes/no (%) 20/49 (29.0%) 34/28 (54.8%)*
Heart Failure, yes/no (%) 5/64 (7.2%) 9/53 (14.5%)
Old Myocardial Infarction, yes/no (%) 3/66 (4.3%) 8/54 (12.9%)
Cardiomyopathy, yes/no (%) 4/65 (5.8%) 4/58 (6.5%)
Chronic Renal Failure, yes/no (%) 7/62 (10.1%) 5/57 (8.1%)
Plasma BNP (pg/ml) 49.6 ± 43.3 106.6 ± 31.5**
Duration after ischemic onset to BNP measurement (hours) 9.2 ± 4.2 9.6 ± 3.8
NIH Stroke Scale score at admission: median (25%–75%) 11 (9–14) 12 (9–18)
Beta-blocker, yes/no (%) 12/57 (17.4%) 13/49 (21.0%)
Angiotensin receptor blocker, yes/no (%) 36/33 (52.2%) 25/37 (40.3%)
Angiotensin converting enzyme inhibitor, yes/no (%) 7/62 (10.1%) 9/53 (14.5%)
E/A 0.8 ± 0.2 1.7 ± 0.6**
LA diameter (mm) 33.9 ± 5.4 41.6 ± 6.8**
LV end-diastolic diameter (mm) 47.9 ± 2.2 47.8 ± 2.2
LV end-systolic diameter (mm) 28.9 ± 2.3 29.1 ± 2.3
Interventricular septum thickness (mm) 12.2 ± 2.8 12.7 ± 2.8
LV posterior wall thickness (mm) 12.3 ± 2.4 12.8 ± 2.5
LV ejection fraction (%) 62.1 ± 10.0 60.8 ± 13.3
LAA flow (cm/s) 76.6 ± 14.1 35.0 ± 22.0**
LA; left atrium. LV; left ventricular. LAA; left atrial appendage.
*: p < 0.01, **: p < 0.001 compared with patients in non-cardioembolic stroke.
The values in this table: means and standard deviations or medians (ranges of 25 to 75 percentile) are given for the continuous variables; numbers 
of patients are given for the categorical variables. %: percentile.BMC Neurology 2008, 8:45 http://www.biomedcentral.com/1471-2377/8/45
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cardioembolic stroke patients, and Af was highly distrib-
uted in cardioembolic stroke (p < 0.001; respectively).
Ultrasonographic variables for cardiac function with TTE
are given in Table 1. E/A and left atrial (LA) diameter were
significantly increased, and LAA flow was significantly
decreased, in cardioembolic stroke compared with non-
cardioembolic stroke (p < 0.001; respectively; E/A was not
available for the permanent Af patients). There were no
significant differences between the two subgroups in the
other cardiac function parameters obtained with ultra-
sonographic examination.
To define the factors that influenced on the plasma BNP,
we screened through the factors in Table 1. Plasma BNP
was significantly associated with blood urea nitrogen, cre-
atinine, Af, heart failure, old myocardial infarction, cardi-
omyopathy, chronic renal failure, E/A, LA diameter, LAA
flow, and LV ejection fraction. To assess the relative
importance of those factors on plasma BNP, we utilized
ordinal multivariate linear regressions. Among them, we
found that Af, heart failure, chronic renal failure, and LA
diameter were statistically significant predictors of plasma
BNP in the multivariable setting (F4,126 = 27.6, p < 0.0001;
adjusted R2 = 0.45). Statistical results of multivariate lin-
ear regression are given in Table 2. In other words, blood
urea nitrogen, creatinine, old myocardial infarction, cardi-
omyopathy, E/A, LAA flow, and LV ejection fraction
turned out not to be associated with plasma BNP after
controlling Af, heart failure, chronic renal failure, and LA
diameter in acute stroke patients. None of stroke size,
NIHSS score, and the duration between plasma BNP
measurement from the stroke onset was associated with
plasma BNP concentration.
To identify the cardioembolic stroke from non-cardioem-
bolic stroke, we have defined the sensitivity and specificity
of plasma BNP, E/A, LA diameter, and LAA flow that had
significant difference between stroke subtypes. E/A was
not available for the permanent Af patients. The sensitiv-
ity and specificity of plasma BNP, E/A, LA diameter, and
LAA flow on classifying cardioembolic stroke from non-
cardioembolic stroke were shown in Figure 1. In Table 3,
we gave cutoffs at the crossed point of sensitivity and spe-
cificity for each of plasma BNP, E/A, LA diameter, and LAA
flow, as well as prediction probabilities, for classifying car-
dioembolic stroke from non-cardioembolic stroke. E/A (>
0.92), LA diameter (> 36 mm), and LAA flow (> 67 cm/s)
achieved high discrimination between the two stroke sub-
types. Those factors had more than 80% overall accuracy
on diagnosing cardioembolic stroke from non-cardioem-
bolic stroke. Plasma BNP (> 77 pg/ml) had slightly weaker
predictive power than the others. However, it also had
76.3% overall accuracy.
To assess the relative importance of Af, mitral regurgita-
tion, plasma BNP (> 77 pg/ml), E/A (> 0.92), LA diameter
(> 36 mm), and LAA flow (> 67 cm/s) on cardioembolic
stroke classification, we utilized ordinal multivariate
logistic regressions. We found that Af, mitral regurgita-
tion, plasma BNP (> 77 pg/ml), and LA dimension (> 36
mm) were statistically significant independent predictors
of cardioembolic stroke in the multivariable setting (Χ2 =
127.5, p < 0.001). Odds ratios (OR) and confidence inter-
vals are given in Table 4.
Discussion
In the present study, we evaluated 131 acute ischemic
stroke patients, 62 patients with cardioembolic stroke, 69
patients with non-cardioembolic stroke (including
atherothrombotic stroke, lacunar stroke, or the other).
With these patients, we assessed the prediction factors of
plasma BNP and whether we could differentiate among
stroke subtypes on the basis of plasma BNP concentra-
tions in addition to patient's clinical variables. Plasma
BNP, in acute ischemic stroke patients, was predicted with
Af, heart failure, chronic renal failure, and LA diameter. In
cardioembolic stroke, the distribution of Af was high,
plasma BNP, E/A, and LA diameter were significantly
increased, and LAA flow was significantly decreased, com-
pared with non-cardioembolic stroke. Af, mitral regurgita-
tion, plasma BNP (> 77 pg/ml), and LA dimension (> 36
mm) were independent predictors of cardioembolic
stroke in the multivariable setting.
BNP at admission was significantly higher in cardioem-
bolic compared with atherothrombotic infarctions [13].
We have found that cardioembolic stroke can be predicted
with Af, mitral regurgitation, plasma BNP, and LA diame-
ter. We could differentiate cardioembolic stroke from
non-cardioembolic stroke with those non-invasive exam-
ination. Recently, Montaner et al. have shown the inde-
pendent predictors of cardioembolic stroke were atrial
fibrillation, other embolic cardiopathies, total anterior
circulation infarction, BNP, and D-dimer [14]. Combin-
Table 2: Least squares linear regression of plasma BNP
Variable Coefficient Std Error T P
Constant -3.175 17.016 -0.187 0.8523
Atrial Fibrillation 46.953 7.214 6.509 < 0.0001
Heart Failure 50.057 11.538 4.338 < 0.0001
Chronic Renal Failure 36.802 11.696 3.147 0.0021
LA dimension 1.404 0.475 2.957 0.0037
In the regression equation, atrial fibrillation, heart failure, and chronic 
renal failure are indicator variables, coded 1 for subjects with past or 
present disease and 0 without disease. Units of the other variables are 
as in Table 1. Summary statistics relating to the regression fit include 
ANOVA (F4,126 = 27.6, p < 0.0001; adjusted R2 = 0.45). Plasma BNP 
was associated with atrial fibrillation, heart failure, chronic renal 
failure, and LA dimension, independently.BMC Neurology 2008, 8:45 http://www.biomedcentral.com/1471-2377/8/45
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Sensitivity (black line) and specificity (gray line) of plasma BNP, E/A, LA diameter, and LAA flow for classifying cardioembolic  stroke from non-cardioembolic stroke Figure 1
Sensitivity (black line) and specificity (gray line) of plasma BNP, E/A, LA diameter, and LAA flow for classifying 
cardioembolic stroke from non-cardioembolic stroke.
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ing their study to our results, plasma BNP can be a surro-
gate marker of cardioembolic stroke with strong
predictive power independent from Af.
It has reported that BNP correlated negatively with LV
ejection fraction [15]. In the present study, plasma BNP
was also associated with the presence of heart failure or LV
ejection fraction in single analysis. However, there is no
longer significant association with LV ejection fraction in
multivariate analysis. Heart failure covered the significant
association of LV ejection fraction with plasma BNP under
multivariate setting. On the other hand, plasma BNP fol-
lowing cerebral ischemia was predicted with any LA/LAA
abnormality, hemoglobin, chronic heart failure, age, and
NIHSS score with 48 patients [16]. In the present study,
plasma BNP was strongly associated with LA/LAA abnor-
mality (LA diameter) in 131 patients. It is widely known
that stressed LA is one of the cardiac sources to secreting
BNP. In their study, age and NIHSS score was also slightly
associated with plasma BNP. However, we could not
detect any association on plasma BNP with age and
NIHSS score. We have found that Af, heart failure, chronic
renal failure, and LA diameter, but not age and NIHSS
score, predict plasma BNP in acute stroke patients. There
are the several reports that supports out results. Plasma
BNP is not only reported to be increased in patients with
Af [4], cardiomyopathy [5], heart failure [6], myocardial
infarction [7], or chronic renal failure [8], but also sug-
gested as related with LA diameter [17].
There are several reports that evaluated the prediction
with plasma BNP on the outcome of acute stroke patients.
However, it is still controversial whether plasma BNP can
predict the outcome of acute stroke patients. High BNP is
independent predictor of myocardial infarction and con-
gestive heart failure risk after stroke or transient ischemic
attack [18,19]. And, elevated BNP predicted mortality
after stroke [20]. High BNP values were associated with
death, a first major cardiovascular event, atrial fibrillation,
stroke or transient ischemic attack, and heart failure [21].
Proportion of patients with good outcome was signifi-
cantly reduced in the group with highest BNP quartile
[22]. However, using multivariate regression analysis, no
significant relation to morbidity and mortality was found
for BNP [22]. It has also shown that elevation of BNP in
48 hours after stroke onset is associated with the develop-
ment of cerebral edema [23].
Handke et al. reported that, independent of the basic
rhythm, there was a close relationship between LAA flow
and elevated thromboembolic risks in the cerebral
ischemia patients [24]. However, to detect LAA flow, TEE
has to be done in the very acute state in stroke. It was
reported that TEE was identified as a risk factor on pneu-
monia [25]. Therefore, a more non-invasive marker to
predict cardioembolic stroke would be of great interest.
From our results, we could differentiate cardioembolic
stroke with plasma BNP independent from Af and LA
diameter. And, LAA flow was not statistically significant
predictor of cardioembolic stroke after controlling Af,
plasma BNP, and LA diameter.
For the limitation of this study, the number of patients
should be listed. We have evaluated 131 acute stroke
patients, and there were 62 cardioembolic stroke patients
and 69 non-cardioembolic stroke patients. Investigating
larger number of acute stroke patients, exact predictive
power of plasma BNP will be detected. Additionally, in
our study, we could not detect any patient with patent
Table 3: Cut off points and prediction probabilities in the stroke.
Variable Cut off CE stroke NCE stroke Overall Accuracy
Plasma BNP 77 pg/ml 47/62 (75.8%) 53/69 (76.8%) 100/131 (76.3%)
E/A 0.92 16/19 (84.2%) 56/69 (81.2%) 72/88 (81.8%)
LA diameter 36 mm 49/62 (79.0%) 57/69 (82.6%) 106/131 (80.9%)
LAA flow 67 cm/s 52/62 (83.9%) 58/69 (84.1%) 110/131 (84.0%)
CE: cardioembolic; NCE non-cardioembolic.
Table 4: Odds ratios and 95% confidence intervals for 
cardioembolic stroke classification, relative to Af, mitral 
regurgitation, plasma BNP, and LA dimension.
n = 131
Af
No 1.00
Yes 146.3 (19.2, 1115.4)**
Mitral regurgitation
No 1.00
Yes 5.9 (1.2, 28.6)*
Plasma BNP
≤ 77 pg/ml 1.00
> 77 pg/ml 5.1 (1.2, 21.4)*
LA dimension
≤ 36 mm 1.00
> 36 mm 17.3 (3.5, 85.8)**
The multivariate odds ratios are determined from logistic regressions 
including all four variables (Χ2 = 127.5, p < 0.001). Plasma BNP was 
independent predictor of cardioembolic stroke, even after controlling 
Af, mitral regurgitation, and LA dimension.
*: p < 0.05; **: p < 0.01.BMC Neurology 2008, 8:45 http://www.biomedcentral.com/1471-2377/8/45
Page 7 of 8
(page number not for citation purposes)
foramen ovale or pulmonary arteriovenous fistula that are
also known to cause cardioembolic stroke. We should
also evaluate plasma BNP in those diseases. Secondly, our
hospital is high care centered hospital. Therefore, usually
heavy symptomatic patients have admitted. And, in the
present study, we have evaluated the patients who had
admitted within 24 hours after their stroke onset. We
think this is the other reason of the high distribution of
cardioembolic patients in this study. Hospital based selec-
tion bias can be exist.
It is important to differentiate cardioembolic stroke from
non-cardioembolic stroke, since cardioembolic stroke
generally results in more severe disability and acute treat-
ment and secondary prevention differ in cardioembolic
stroke from non-cardioembolic stroke. However, it is dif-
ficult to diagnose the subtypes of ischemic stroke accu-
rately at admission. We have evaluated the predictive
factors of cardioembolic stroke. From our results, it was
suggested that cardioembolic stroke was strongly pre-
dicted with Af, plasma BNP, and LA diameter.
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